10X Genomics Inc (TXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -31,251 | -112,485 | -18,762 | N/A |
| Depreciation Amortization | 7,066 | 3,905 | 4,305 | N/A |
| Accounts receivable | -5,284 | -14,747 | -5,131 | N/A |
| Accounts payable and accrued liabilities | 4,901 | 2,587 | 3,034 | N/A |
| Other Working Capital | 44,764 | 28,015 | 1,948 | N/A |
| Other Operating Activity | 14,431 | 16,316 | 3,907 | 0 |
| Operating Cash Flow | $34,627 | $-76,409 | $-10,699 | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -42,742 | -6,284 | -3,756 | N/A |
| Purchase Sale Intangibles | -25 | -425 | N/A | N/A |
| Other Investing Activity | -25 | -425 | 0 | 0 |
| Investing Cash Flow | $-42,767 | $-6,709 | $-3,756 | $N/A |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | 11,000 | N/A | N/A | N/A |
| Debt Issued | N/A | 19,512 | N/A | N/A |
| Debt Repayment | N/A | -773 | -393 | N/A |
| Common Stock Issued | 414,590 | 1,798 | 1,092 | N/A |
| Common Stock Repurchased | N/A | N/A | -80 | N/A |
| Other Financing Activity | -11,000 | 84,830 | 19,964 | 0 |
| Financing Cash Flow | $414,590 | $105,367 | $20,583 | $N/A |
| Exchange Rate Effect | -45 | -18 | -14 | N/A |
| Beginning Cash Position | 70,088 | 47,857 | 41,743 | N/A |
| End Cash Position | 476,493 | 70,088 | 47,857 | N/A |
| Net Cash Flow | $406,405 | $22,231 | $6,114 | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | 34,627 | -76,409 | -10,699 | N/A |
| Capital Expenditure | -42,742 | -6,284 | -3,756 | N/A |
| Free Cash Flow | -8,115 | -82,693 | -14,455 | 0 |